Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Market data
Price feed temporarily unavailable for BPTH.
5-year trend
What this company does
ITEM 1. BUSINESS Overview We are a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic,…
AI summary unavailable — showing raw filing excerpt
Generated from BPTH's filing dated 2021-03-09
Key risks
ITEM 1A. RISK FACTORS Risk Factor Summary We are providing the following summary of the risk factors disclosed in this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the risk factors disclosed in this Form 10-K in their entirety for additional information regarding the material factors that make an investment in the Company speculative or risky. ●We are a clinical stage biotechnology company with no significant revenue. We have incurred significant operating losses since our inception, and we expect to incur losses for the foreseeable future and may never achieve profitability. ●We…
AI summary unavailable — showing raw filing excerpt
Generated from BPTH's filing dated 2021-03-09
Profitability
Return on equity
-6424.7%
76.2%Return on assets
-254.8%
49.0%Leverage
Debt / equity
24.21×
284.3%Debt / assets
96.0%
11.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-270.0K | +90.5% | — |
Q3 2025 2025-09-30 | — | — | $-976.0K | +53.9% | — |
Q2 2025 2025-06-30 | — | — | $-4.6M | -146.0% | — |
Q1 2025 2025-03-31 | — | — | $-2.9M | +9.7% | — |
Q4 2024 2024-12-31 | — | — | $-2.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-2.1M | +33.9% | — |
Q2 2024 2024-06-30 | — | — | $-1.9M | +55.9% | — |
Q1 2024 2024-03-31 | — | — | $-3.2M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on BPTH — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for BPTH in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns BPTH
Institutional value
$15.1K
Total shares held
32.4K
Distinct holders
2
-21 vs prior
As of
2025-03-31
Prior: 2024-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JONES FINANCIAL COMPANIES LLLP | 1.3K | $9.8K | — | New |
| 2 | XTX Topco Ltd | 31.1K | $5.3K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once BPTH's latest filing finishes processing.